The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
Open accessAbstract
Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in type 1 diabetic (T1D) patients. Nine T1D subjects were treated with 2–4 mg/day rapamycin orally for 3 months and 4.5 × 106 IU IL-2 s.c. three times per week for 1 month. β-Cell function was monitored by measuring C-peptide. Immunologic changes were monitored using flow cytometry and serum analyses. Regulatory T cells (Tregs) increased within the first month of therapy, yet clinical and metabolic data demonstrated a transient worsening in all subjects. The increase in Tregs was transient, paralleling IL-2 treatment, whereas the response of Tregs to IL-2, as measured by STAT5 phosphorylation, increased and persisted after treatment. No differences were observed in effector T-cell subset frequencies, but an increase in natural killer cells and eosinophils occurred with IL-2 therapy. Rapamycin/IL-2 therapy, as given in this phase 1 study, resulted in transient β-cell dysfunction despite an increase in Tregs. Such results highlight the difficulties in translating therapies to the clinic and emphasize the importance of broadly interrogating the immune system to evaluate the effects of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment
Delgoffe, G. M., Kole, T. P., Zheng, Y., Zarek, P. E., Matthews, K. L., Xiao, B., Worley, P. F., Kozma, S. C., & Powell, J. D. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.014 · Cited by 1,284
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Self-citationInterleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108188 · Cited by 1,119
Delgoffe, G. M., Pollizzi, K. N., Waickman, A. T., Heikamp, E., Meyers, D. J., Horton, M. R., Xiao, B., Worley, P. F., & Powell, J. D. (2011) · Nature Immunology · doi:10.1038/ni.2005 · Cited by 1,111
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationMalek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Immunoregulatory functions of mTOR inhibition
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2546 · Cited by 847
Verge, C. F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H. P., Eisenbarth, G. S., & Jackson, R. A. (1996) · Diabetes · doi:10.2337/diab.45.7.926 · Cited by 827
Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases
Buckner, J. H. (2010) · Nature Reviews Immunology · doi:10.1038/nri2889 · Cited by 789
Self-citationRegulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., & Klatzmann, D. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105143 · Cited by 762
Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Self-citationOrban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Self-citationBielekova, B., Catalfamo, M., Reichert-Scrivner, S., Packer, A., Cerna, M., Waldmann, T. A., McFarland, H., Henkart, P. A., & Martin, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601335103 · Cited by 597
Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?
Huehn, J., Polansky, J. K., & Hamann, A. (2009) · Nature Reviews Immunology · doi:10.1038/nri2474 · Cited by 526
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60931-8 · Cited by 493
The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism
Powell, J. D., & Delgoffe, G. M. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.002 · Cited by 486
Grinberg-Bleyer, Y., Baeyens, A., You, S., Elhage, R., Fourcade, G., Gregoire, S., Cagnard, N., Carpentier, W., Tang, Q., Bluestone, J., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100209 · Cited by 433
Self-citationWherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Self-citationWieczorek, G., Asemissen, A., Model, F., Turbachova, I., Floess, S., Liebenberg, V., Baron, U., Stauch, D., Kotsch, K., Pratschke, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2361 · Cited by 317
Greenbaum, C. J., Mandrup-Poulsen, T., McGee, P. F., Battelino, T., Haastert, B., Ludvigsson, J., Pozzilli, P., Lachin, J. M., Kolb, H., & The Type 1 Diabetes Trial Net Research Group and the European C-Peptide Trial Study Group (2008) · Diabetes Care · doi:10.2337/dc07-2451 · Cited by 285
Self-citationLong, S. A., Cerosaletti, K., Bollyky, P. L., Tatum, M., Shilling, H., Zhang, S., Zhang, Z.-Y., Pihoker, C., Sanda, S., Greenbaum, C., et al. (2010) · Diabetes · doi:10.2337/db09-0694 · Cited by 283
Self-citationAutoimmune mechanisms in type 1 diabetes
Knip, M., & Siljander, H. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.04.008 · Cited by 263
Maier, L. M., Anderson, D. E., Severson, C. A., Baecher-Allan, C., Healy, B., Liu, D. V., Wittrup, K. D., De Jager, P. L., & Hafler, D. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1541 · Cited by 175
Robb, R. J., & Kutny, R. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.3.855 · Cited by 165
Natural killer cells in human autoimmune diseases
Schleinitz, N., Vély, F., Harlé, J., & Vivier, E. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03360.x · Cited by 158
Sirolimus Is Associated With Reduced Islet Engraftment and Impaired β-Cell Function
Zhang, N., Su, D., Qu, S., Tse, T., Bottino, R., Balamurugan, A. N., Xu, J., Bromberg, J. S., & Dong, H. H. (2006) · Diabetes · doi:10.2337/db06-0173 · Cited by 158
Gottlieb, P. A., Quinlan, S. C., Krause-Steinrauf, H. J., Greenbaum, C. J., Wilson, D. M., Rodriguez, H., Schatz, D., Moran, A., Lachin, J. M., Skyler, J. S., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1349 · Cited by 158
Self-citationCentral Role for Interleukin-2 in Type 1 Diabetes
Hulme, M. A., Wasserfall, C. H., Atkinson, M. A., & Brusko, T. M. (2011) · Diabetes · doi:10.2337/db11-1213 · Cited by 146
Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells
Monti, P., Scirpoli, M., Maffi, P., Piemonti, L., Secchi, A., Bonifacio, E. E., Roncarolo, M., & Battaglia, M. (2008) · Diabetes · doi:10.2337/db08-0138 · Cited by 143
Rabinovitch, A., Suarez‐Pinzon, W. L., Shapiro, A. M. J., Rajotte, R. V., & Power, R. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.638 · Cited by 134
Self-citationTurnquist, H. R., Cardinal, J. S., Macedo, C., Rosborough, B. R., Sumpter, T. L., Geller, D. A., Metes, D., & Thomson, A. W. (2010) · Blood · doi:10.1182/blood-2009-10-251488 · Cited by 126
Paolo, S. D., Teutonico, A., Leogrande, D., Capobianco, C., & Schena, P. F. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030196 · Cited by 121
Distinct Phenotype and Function of NK Cells in the Pancreas of Nonobese Diabetic Mice
Brauner, H., Elemans, M., Lemos, S., Broberger, C., Holmberg, D., Flodström‐Tullberg, M., Kärre, K., & Höglund, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0804358 · Cited by 99
Bernstein, Z., Porter, M., Gould, M., Lipman, B., Bluman, E., Stewart, C., Hewitt, R. M., Fyfe, G., Poiesz, B. J., & Caligiuri, M. A. (1995) · Blood · doi:10.1182/blood.v86.9.3287.bloodjournal8693287 · Cited by 92
Orange, J. S., Roy–Ghanta, S., Mace, E. M., Maru, S. Y., Rak, G. D., Sanborn, K. B., Fasth, A. L., Saltzman, R. W., Paisley, A., Monaco-Shawver, L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44862 · Cited by 91
Epigenetic quantification of tumor-infiltrating T-lymphocytes
Sehouli, J., Loddenkemper, C., Cornu, T. I., Schwachula, T., Hoffmüller, U., Grützkau, A., Lohneis, P., Dickhaus, T., Gröne, J., Kruschewski, M., et al. (2011) · Epigenetics · doi:10.4161/epi.6.2.13755 · Cited by 85
IL-2 signaling and CD4+CD25+Foxp3+ regulatory T cells
Laurence, A. T. (2007) · Frontiers in bioscience · doi:10.2741/2773 · Cited by 84
Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts
Koulmanda, M., Budo, E., Bonner‐Weir, S., Qipo, A., Putheti, P., Degauque, N., Shi, H., Fan, Z., Flier, J. S., Auchincloss, H., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705863104 · Cited by 75
Beta cell function during rapamycin monotherapy in long-term type 1 diabetes
Piemonti, L., Maffi, P., Monti, L., Lampasona, V., Perseghin, G., Magistretti, P., Secchi, A., & Bonifacio, E. E. (2010) · Diabetologia · doi:10.1007/s00125-010-1959-6 · Cited by 40
Rapamycin Induces Autophagy in Islets: Relevance in Islet Transplantation
Tanemura, M., Saga, A., Kawamoto, K., MACHIDA, T., Deguchi, T., Nishida, T., Sawa, Y., Doki, Y., Mori, M., & Ito, T. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.10.032 · Cited by 38
Varker, K. A., Kondadasula, S. V., Go, M. R., Lesinski, G. B., Ghosh-Berkebile, R., Lehman, A., Monk, J. P., Olencki, T. E., Kendra, K. L., & Carson, W. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1159 · Cited by 31
Cited by
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033
Self-citationHarnessing the plasticity of CD4+ T cells to treat immune-mediated disease
DuPage, M., & Bluestone, J. A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.18 · Cited by 513
Self-citationHartemann, A., Bensimon, G., Payan, C. A., Jacqueminet, S., Bourron, O., Nicolas, N., Fonfrede, M., Rosenzwajg, M., Bernard, C., & Klatzmann, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70113-x · Cited by 428
Bailey-Bucktrout, S. L., Martinez-Llordella, M., Zhou, X., Anthony, B., Rosenthal, W., Luche, H., Fehling, H. J., & Bluestone, J. A. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.016 · Cited by 396
Self-citation
Metadata
- Authors
- Long, S. A., Rieck, M., Sanda, S., Bollyky, J. B., Samuels, P. L., Goland, R., Ahmann, A., Rabinovitch, A., Aggarwal, S., Phippard, D., Turka, L. A., Ehlers, M. R., Bianchine, P. J., Boyle, K. D., Adah, S. A., Bluestone, J. A., Buckner, J. H., & Greenbaum, C. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-08-17
- Volume
- 61
- Issue
- 9
- Pages
- 2340-2348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2163665000
- Cited by
- 314
- References
- 42
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.